Syndax Pharmaceuticals (SNDX) Short term Debt (2015 - 2024)

Syndax Pharmaceuticals' Short term Debt history runs 5 years deep, the most recent figure standing at $12.1 million for Q4 2024.

• In Q4 2024, Short term Debt changed N/A year-over-year to $12.1 million; the TTM figure through Dec 2024 stood at $12.1 million (changed N/A YoY), while the FY2024 annual figure was $12.1 million, changed N/A from the prior year.
• Short term Debt was $12.1 million for Q4 2024 at Syndax Pharmaceuticals, up from $7.2 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $12.1 million in Q4 2024 to a low of $187000.0 in Q4 2021.
• Historically, Short term Debt has averaged $5.8 million across 4 years, with a median of $5.8 million in 2021.
• The sharpest annual moves came in 2021 and 2022: Short term Debt slumped 91.82% in 2021, then advanced 2.59% in 2022.
• A 4-year view of Short term Debt shows it stood at $2.3 million in 2020, then plunged by 91.82% to $187000.0 in 2021, then soared by 3756.68% to $7.2 million in 2022, then jumped by 68.0% to $12.1 million in 2024.
• The last three Short term Debt figures came in at $12.1 million (Q4 2024), $7.2 million (Q2 2022), and $3.6 million (Q1 2022), per Business Quant data.